Cargando…

Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature

Cushing’s disease (CD) is caused by endogenous hypercortisolism as a result of adrenocorticotropin (ACTH) secretion from a pituitary tumor. The condition is associated with multiple comorbidities and increased mortality. First-line therapy for CD is pituitary surgery, performed by an experienced pit...

Descripción completa

Detalles Bibliográficos
Autores principales: Perosevic, Milica, Tritos, Nicholas A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151255/
https://www.ncbi.nlm.nih.gov/pubmed/37143705
http://dx.doi.org/10.2147/DDDT.S315359
_version_ 1785035501655293952
author Perosevic, Milica
Tritos, Nicholas A
author_facet Perosevic, Milica
Tritos, Nicholas A
author_sort Perosevic, Milica
collection PubMed
description Cushing’s disease (CD) is caused by endogenous hypercortisolism as a result of adrenocorticotropin (ACTH) secretion from a pituitary tumor. The condition is associated with multiple comorbidities and increased mortality. First-line therapy for CD is pituitary surgery, performed by an experienced pituitary neurosurgeon. Hypercortisolism may often persist or recur after initial surgery. Patients with persistent or recurrent CD will generally benefit from medical therapy, often administered to patients who underwent radiation therapy to the sella and are awaiting its salutary effects. There are three groups of medications directed against CD, including pituitary-targeted medications that inhibit ACTH secretion from tumorous corticotroph cells, adrenally-directed medications that inhibit adrenal steroidogenesis and a glucocorticoid receptor (GR) antagonist. The focus of this review is osilodrostat, a steroidogenesis inhibitor. Osilodrostat (LCI699) was initially developed to lower serum aldosterone levels and control hypertension. However, it was soon realized that osilodrostat also inhibits 11-beta hydroxylase (CYP11B1), leading to a reduction in serum cortisol levels. The focus of drug development then shifted from treatment of hypertension to treatment of hypercortisolism in CD. In a series of studies (LINC 1 through 4), osilodrostat was shown to be effective in normalizing 24-h urinary free cortisol (UFC) in the majority of treated patients and was approved for patients with CD who have failed surgery or are not surgical candidates. Further study is needed to examine the role of combination therapy as well as long-term outcomes of treated patients. Osilodrostat was shown to have an overall good safety profile. Most common adverse effects include nausea, headache, fatigue, arthralgias, dizziness, prolonged QT(c) interval, hypokalemia. In females, the drug can cause hirsutism and acne. Osilodrostat is administered twice daily, making it a good choice for patients with difficulty adhering to more complex regimens. Osilodrostat has an important, albeit adjunctive, role in the management of patients with CD.
format Online
Article
Text
id pubmed-10151255
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-101512552023-05-03 Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature Perosevic, Milica Tritos, Nicholas A Drug Des Devel Ther Review Cushing’s disease (CD) is caused by endogenous hypercortisolism as a result of adrenocorticotropin (ACTH) secretion from a pituitary tumor. The condition is associated with multiple comorbidities and increased mortality. First-line therapy for CD is pituitary surgery, performed by an experienced pituitary neurosurgeon. Hypercortisolism may often persist or recur after initial surgery. Patients with persistent or recurrent CD will generally benefit from medical therapy, often administered to patients who underwent radiation therapy to the sella and are awaiting its salutary effects. There are three groups of medications directed against CD, including pituitary-targeted medications that inhibit ACTH secretion from tumorous corticotroph cells, adrenally-directed medications that inhibit adrenal steroidogenesis and a glucocorticoid receptor (GR) antagonist. The focus of this review is osilodrostat, a steroidogenesis inhibitor. Osilodrostat (LCI699) was initially developed to lower serum aldosterone levels and control hypertension. However, it was soon realized that osilodrostat also inhibits 11-beta hydroxylase (CYP11B1), leading to a reduction in serum cortisol levels. The focus of drug development then shifted from treatment of hypertension to treatment of hypercortisolism in CD. In a series of studies (LINC 1 through 4), osilodrostat was shown to be effective in normalizing 24-h urinary free cortisol (UFC) in the majority of treated patients and was approved for patients with CD who have failed surgery or are not surgical candidates. Further study is needed to examine the role of combination therapy as well as long-term outcomes of treated patients. Osilodrostat was shown to have an overall good safety profile. Most common adverse effects include nausea, headache, fatigue, arthralgias, dizziness, prolonged QT(c) interval, hypokalemia. In females, the drug can cause hirsutism and acne. Osilodrostat is administered twice daily, making it a good choice for patients with difficulty adhering to more complex regimens. Osilodrostat has an important, albeit adjunctive, role in the management of patients with CD. Dove 2023-04-27 /pmc/articles/PMC10151255/ /pubmed/37143705 http://dx.doi.org/10.2147/DDDT.S315359 Text en © 2023 Perosevic and Tritos. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Perosevic, Milica
Tritos, Nicholas A
Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature
title Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature
title_full Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature
title_fullStr Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature
title_full_unstemmed Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature
title_short Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature
title_sort clinical utility of osilodrostat in cushing’s disease: review of currently available literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151255/
https://www.ncbi.nlm.nih.gov/pubmed/37143705
http://dx.doi.org/10.2147/DDDT.S315359
work_keys_str_mv AT perosevicmilica clinicalutilityofosilodrostatincushingsdiseasereviewofcurrentlyavailableliterature
AT tritosnicholasa clinicalutilityofosilodrostatincushingsdiseasereviewofcurrentlyavailableliterature